The Efficacy of Continuing Osimertinib With Platinum Pemetrexed Chemotherapy Upon Progression in Patients With Metastatic NSCLC Harboring Sensitizing EGFR Mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Lung Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations
Lung Cancer 2024 Nov 25;199(xx)108040, T Patil, D Gao, A Watson, M Sakamoto, Y Nie, A Gibson, ML Dean, BA Yoder, E Miller, M Stalker, DL Aisner, PA Bunn, EL Schenk, ME Marmarelis, C Bennati, V Navani, Y Zhang, DR CamidgeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.